Gene knockout experiments further demonstrated that CCL2 inhibition reduces BMDM recruitment, delays tumor progression, and prolongs survival in murine models, suggesting that the CCL2/CCR2 axis is a potential therapeutic target for GBM immunotherapy [67]. This evidence concerns the gene CCL2 and neoplasm.